GE to invest €150 million in biopharmaceutical manufacturing campus in Cork, Ireland, and establish advanced manufacturing training centre at NIBRT
Ireland’s Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor TD, today announced that GE (NYSE:GE) is to invest €150 million in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland’s strategic site at Loughbeg, Ringaskiddy, Co. Cork. GE BioPark Cork, subject to contract and planning approvals, will feature Europe’s first KUBio™, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, and will serve as focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland.
Building manufacturing capacity
GE BioPark Cork is expected to be home to more than 500 new jobs when fully operational; 400 with biopharma companies and a further 100 employed directly by GE. The construction phase, subject to planning approvals, is expected to begin by mid- 2017 and create up to 800 construction jobs. The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Developing bio-manufacturing skills for 1,500 bio-professionals per year
To further develop biopharma manufacturing skills and expertise in Ireland, GE and the National Institute for Bioprocessing Research and Training (NIBRT) also announced today their plan to create a NIBRT-GE Single-use Centre of Excellence at NIBRT’s Dublin facility. NIBRT expects to train up to 1,500 bioprocessing professionals annually on next-generation biologic manufacturing technologies. These exceptional technologies for biopharma manufacturing will be used in GE BioPark Cork’s manufacturing facilities.
GE BioPark Cork will be a GE-managed campus including four fully-equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE running centralised shared utilitiesand site services.
Patient demand for innovative medicines is driving rapid global growth of the biopharmaceutical industry, resulting in significant need for more production capacity. GE’s KUBio enables pharmaceutical companies to quickly deploy new biologics manufacturing capacity and bring medicines to market faster. KUBios increase manufacturing flexibility and are between 25 and 50 percent more cost-effective to build than comparable traditional facilities. Carbon dioxide emissions can be reduced by 75 percent and water and energy use by approximately 80 percent. Build time can be shortened to 18 months from the usual 3 years.
Minister Mitchell O’Connor said: “The Biopharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of the fastest growing sectors. I am delighted that GE is making a significant investment in Cork. This is a further testament to our talented workforce. All investment and jobs created has a positive knock on effect on the wider region. Over 28,000 people currently work in biopharma and 6,000 of those work in biologics. This subsector is expected to double in the coming years and will provide both a challenge and an opportunity for the industry and training providers to collaborate on promoting the range of career opportunities available. I welcome GE’s commitment to Ireland and wish them every success in the future.”
